As of Wednesday close, Intra-Cellular Therapies Inc.’s (NASDAQ:ITCI) stock was down -$1.68, moving down -3.18 percent to $51.19. The average number of shares traded per day over the past five days has been 538,700 shares. 3 times new highs have been achieved over the past 5 days, with a $1.28 gain in that time frame. In the last twenty days, the average volume was 783,430, while in the previous 50 days, it was 731,978.
Since last month, ITCI stock rose 14.60%. Shares of the company fell to $43.86 on 11/02/22, the lowest level in the past month. A 52-week high of $66.00 was reached on 04/07/22 after having rallying from a 52-week low of $34.43. Since the beginning of this year, ITCI’s stock price has dropped by -2.20% or -$1.15, and marked a new high 15 times. However, the stock has declined by -22.44% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
ITCI stock investors should be aware that Intra-Cellular Therapies Inc. (ITCI) stock had its last reported insider trading activity 17 days ago on Nov 07. MARCUS JOEL S, the Director of the company, disposed of 10,000 shares for $52.30 on Nov 07. It resulted in a $523,023 divestment by the insider. Hineline Lawrence J. sold 65,164 shares at an average price of $45.63 on Sep 21. The insider now owns 0 shares following the transaction. On Aug 11, Director VAN NOSTRAND ROBERT L sold 30,000 shares at $57.13 apiece. The transaction was valued at $1,713,975.
The stock’s beta is 1.16. Besides these, the trailing price-to-sales (P/S) ratio of 25.11, the price-to-book (PB) ratio of 7.06.
In the three months ended June 29, Intra-Cellular Therapies Inc.’s quick ratio stood at 9.50, while its current ratio was 9.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 91.40% percent. Based on annual data, ITCI earned $75.77 million in gross profit and brought in $83.8 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -68.40%. Return on equity (ROE) for the past 12 months was -45.50%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ITCI’s revenue rose 69.1% to $55.58 million during the quarter, while net income inched up to $71.87 million. While analysts expected Intra-Cellular Therapies Inc. to report -$0.76 quarterly earnings, the actual figure was -$0.92 per share, beating the consensus estimate by -21.10%. During the quarter, the company generated -$55.23 million in EBITDA. The liabilities of Intra-Cellular Therapies Inc. were 96.58 million at the end of its most recent quarter ended June 29, and its total debt was $26.82 million. The value of shareholders’ equity is $94.7 million.
This quick technical analysis looks at Intra-Cellular Therapies Inc.’s (ITCI) price momentum. With a historical volatility rate of 38.60%, the RSI 9-day stood at 53.31% on 23 November.
With respect to its five-day moving average, the current Intra-Cellular Therapies Inc. price is up by +2.56% percent or $1.28. At present, ITCI shares trade +11.45% above its 20-day simple moving average and -10.33% percent below its 100-day simple moving average. However, the stock is currently trading approximately +2.07% above its SMA50 and +0.14% above its SMA200.
Stochastic coefficient K was 68.06% and Stochastic coefficient D was 73.89%, while ATR was 2.39. Given the Stochastic reading of 43.02% for the 14-day period, the RSI (14) reading has been calculated as 54.25%. As of today, the MACD Oscillator reading stands at 0.56, while the 14-day reading stands at 0.61.
Intra-Cellular Therapies Inc. downgraded its rating on Intra-Cellular Therapies Inc. (NASDAQ: ITCI) to a Neutral in a note to investors on August 22, 2022. The analysts firm previously had a Buy rating on the stock.Intra-Cellular Therapies Inc. (ITCI) has been rated Buy by analysts. According to 0 brokerage firms, ITCI is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Intra-Cellular Therapies Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $69.00, the current consensus forecast for the stock is $50.00 – $93.00. Based on these forecasts, analysts predict Intra-Cellular Therapies Inc. (ITCI) will achieve an average price target of $68.69.